Why Healthcare ETFs Are Hovering Around One-Year Highs

Healthcare ETFs are hovering near 52-week highs as earnings prospects improve, clinical breakthroughs advance and GLP-1 demand expands. Explore five ETFs riding the rally.

Zacks Investment Research • 8 hours ago

Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?

The Invesco Biotechnology & Genome ETF (PBE) made its debut on 06/23/2005, and is a smart beta exchange traded fund that provides broad exposure to the Health Care ETFs category of the market.

Zacks Investment Research • Oct 14, 2026

Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?

Launched on June 23, 2005, the Invesco Biotechnology & Genome ETF (PBE) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Biotech segment of the equity market.

Zacks Investment Research • Oct 13, 2026

PBE vs. RSPH: Is a Biotech ETF or Equal-Weight Healthcare ETF the Better Choice for Investors?

PBE offers a higher dividend yield and has delivered stronger one-year total returns. RSPH offers a more affordable expense ratio and a significantly lower historical drawdown.

The Motley Fool • Sep 15, 2026

iShares' IYH or Invesco's PBE: Which Healthcare ETF Is the Better Long-Term Buy?

iShares U.S. Healthcare ETF offers a more diversified portfolio and lower expense ratio than Invesco Biotechnology & Genome ETF. Invesco Biotechnology & Genome ETF delivered a higher 1-year total return but has experienced significantly larger historical drawdowns.

The Motley Fool • Sep 9, 2026

VanEck Pharmaceutical ETF vs. Invesco Biotech ETF: Which Fund Fits Your Investing Style?

VanEck Pharmaceutical ETF features a lower expense ratio of 0.36% compared to 0.58% for Invesco Biotechnology & Genome ETF. Invesco Biotechnology & Genome ETF delivered a higher 1-year total return of 47.3% but experienced a significantly deeper maximum drawdown of 34.7%.

The Motley Fool • Aug 12, 2026

XLV vs PBE: Is a Low-Cost Healthcare ETF the Better Buy Than a Focused Biotech Specialist?

State Street Health Care Select Sector SPDR ETF offers a significantly lower expense ratio of 0.08% compared to 0.58% for Invesco Biotechnology & Genome ETF Invesco Biotechnology & Genome ETF holds a concentrated basket of 30 biotech firms, whereas State Street Health Care Select Sector SPDR ETF provides exposure to 60 broad healthcare companies State Street Health Care Select Sector SPDR ETF has experienced a shallower maximum drawdown and lower volatility than Invesco Biotechnology & Genome ETF over the last five years

The Motley Fool • Aug 1, 2026

VHT vs. PBE: Which Health Care ETF Is the Better Buy?

The Vanguard Health Care ETF (VHT) offers broader health care exposure and has a a lower expense ratio than the Invesco Biotechnology & Genome ETF (PBE). PBE has delivered a stronger 1-year return, but has also experienced a much steeper 5-year maximum drawdown.

The Motley Fool • Jul 30, 2026

ETF Showdown: XBI vs PBE, Which Biotech Fund Wins?

At first glance, SPDR S&P Biotech ETF (NYSEARCA:XBI) and Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) look like two flavors of the same bet on drug discovery.

24/7 Wall Street • Jul 24, 2026

Biotech ETFs Gain Momentum via AI Drug Discovery & Surging M&A

The biotechnology sector has broken out of its multiyear bear market. As macroeconomic headwinds moderate and regulatory environments stabilize, biotech ETFs are surging.

ETF Trends • Jun 23, 2026